Senate CEO Hearing On Drug Prices Could (Almost) Have Taken Place Five Years Ago

Discussion around the landmark developments in pricing reform established by the Inflation Reduction Act of 2022 were largely absent from the hearing involving Johnson & Johnson’s Joaquin Duato, Merck’s Robert Davis and Bristol Myers Squibb’s Chris Boerner.